Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| Estrogen receptor (ERα) | 70-80% | ER expression (endometrioid) | Wikipedia |
| Folate receptor alpha | 60-80% | IHC, any expression | Wikipedia |
| PIK3CA / PI3K-alpha | 45-55% | Activating mutation | cBioPortal (TCGA) |
| WRN helicase (MSI-high cancers) | 30% | MSI-H | |
| KRAS | 15-20% | Any KRAS mutation | cBioPortal (TCGA) |
| WEE1 | n/a | Uterine serous carcinoma context | Wikipedia |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
5 cell lines, 1 mouse models and 5 repositories are listed for this cancer. See them →